PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:
A61M 37/00, A61N 1/32

A1

(11) International Publication Number:

WO 97/04832

(43) International Publication Date:

13 February 1997 (13.02.97)

(21) International Application Number:

PCT/US96/12244

(22) International Filing Date:

25 July 1996 (25.07.96)

(30) Priority Data:

507,060 25 July 1995 (25.07.95) US 511,583 4 August 1995 (04.08.95) US 574,377 18 December 1995 (18.12.95) US 626,021 1 April 1996 (01.04.96) US

(71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOL-OGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).

(72) Inventors: MITRAGOTRI, Samir, S.; Number 23, 402 Highland Avenue, Somerville, MA 02138 (US). PLIQUETT, Uwe; Gohliser Strasse 14, D-04105 Leipzig (DE). JOHNSON, Mark, E.; 33 Brainerd Road, Allston, MA 02134 (US). PISHKO, Michael; 38 Rawson Road, Arlington, MA 02174 (US). KOST, Joseph; 54 Hshita Street, 84965 Omer (IL). LANGER, Robert, S.; 77 Lombard Street, Newton, MA 02158 (US). WEAVER, James, C.; 248 Old Lancaster Road, Sudbury, MA 01776 (US). BLANKSCHTEIN, Daniel; Apartment 5, 26 Egmont Street, Brookline, MA 02146 (US).

(74) Agent: PABST, Patrea, L.; Amall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report. With amended claims.

Date of publication of the amended claims:

3 April 1997 (03.04.97)

(54) Title: ENHANCED TRANSDERMAL TRANSPORT USING ULTRASOUND

(57) Abstract

Several means for enhancing transdermal transport of drugs and analytes have been developed, including the use of low frequence ultrasound, chemical modifiers of permeability and/or cavitation, iontophoresis and/or electroporation (electric fields), pressure and/or vacuum (physical enhancers), and magnetic force fields. Applications of low-frequency (approximately 20 KHz to 1 MHz) ultrasound enhances transdermal transport of drugs and measurements of the concentration of analytes in body fluids such as blood or lymph. Delivery can be further enhanced or controlled through the use of carriers for the drugs, such as liposomes or microparticles, using a wide range of ultrasound frequency ranges and intensities. The microparticles are preferably small, and may have surfaces with increased hydrophilicity or lipophilicity to further enhance transport.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	*1		
AT	Austria	GE	United Kingdom	MW	Malawi
ΑU	Australia	GN	Georgia	MX	Mexico
BB	Barbados	GR	Guinea	NE	Niger
BE	Belgium	HU	Greece	NL	Netherlands
BF	Burkina Faso		Hungary	NO	Norway
BG	Bulgaria	IE IT	Ireland	NZ	New Zealand
BJ	Benin		Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	КР	Democratic People's Republic	SD	Sudan
CG	Congo	KR	of Korea	SE	Sweden
СН	Switzerland	KZ	Republic of Korea	SG	Singapore
CI	Côte d'Ivoire	LI	Kazakhstan	SI	Slovenia
CM	Cameroon	LK	Liechtenstein	SK	Slovakia
CN	China	LR	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LT	Liberia	SZ	Swaziland
CZ	Czech Republic	LU	Lithuania	TD	Chad
DE	Germany	LV	Luxembourg	TG	Togo
DK	Denmark	MC	Larvia	TJ	Tajikistan
EE	Estonia	MD	Monaco	TT	Trinidad and Tobago
ES	Spain	MG	Republic of Moldova Madapascar	UA	Ukraine
		MG	(VLACIADASCAT		

AMENDED CLAIMS

[received by the International Bureau on 6 March 1997 (06.03.97); original claims 1-24 replaced by amended claims 1-24 (3 pages)]

- 1. A use of an apparatus for enhancing transport of molecules across the skin comprising means for applying ultrasound to the skin, wherein the ultrasound is application at a frequency of between 20 kHz and less than 1 MHz for a period of time effective to transport the molecules through the skin.
- 2. The use of claim 1 wherein the molecules are drugs to be administered to a person in need thereof.
- 3. The use of claim 1 wherein the molecules are analytes present in blood, lymph or interstitial fluid.
- 4. The use of claim 1 wherein the frequency is between 20 and 45 kHz.
- 5. The use of claim 1 wherein the intensity is between zero and 1 W/cm^2 .
- 6. The use of claim 5 wherein the intensity is between 12.5 mW/cm^2 and 225 mW/cm^2 .
- 7. A method of using the apparatus of any of claims 1-6 to enhance transfer of molecules through the skin by applying ultrasound at a frequency of between 20 kHz and less than 1 MHz for a period of time effective to transport the molecules through the skin.
- 8. A method for extracting an analyte to be measured in a blood or body fluid sample comprising applying at an appropriate site for extraction of a sample an effective amount of ultrasound and collecting the extracted sample, wherein the ultrasound is applied at a frequency between 20 kHz and less than 10 MHz.
- 9. The method of claim 8 wherein the ultrasound is applied at a frequency of between 20 kH and less than 1 MHz.
- 10. An apparatus for enhancing transdermal transport of molecules comprising means for administering to the skin an effective amount of ultrasound for transdermal transport of molecules in combination with an enhancer selected from the group consisting of chemical enhancer combinations of agents enhancing solubility of the molecules to be transported with agents enhancing the fluidity of lipid

bilayers, mechanical force fields, osmotic force fields, magnetic force fields and electric force fields.

- 11. The apparatus of claim 9 wherein the ultrasound is administered at a frequency of less than 2.5 MHz.
- 12. The apparatus of claim 9 wherein the ultrasound is administered at a frequency of 1 MHz or less.
- 13. The apparatus of claim 9 wherein the combination is linoleic acid in an ethanol solution.
- 14. The apparatus of claim 9 wherein the ultrasound is administered in combination with an electric force field selected from the group consisting of electroporation and iontophoresis.
- 15. The apparatus of claim 13 wherein the electric field is pulsed.
- 16. The apparatus of claim 9 wherein the ultrasound is administered in combination with a magnetic force field.
- 17. The apparatus of claim 9 wherein the ultrasound is administered in combination with a mechanical force field created by pressure or vacuum.
- 18. The apparatus of claim 9 wherein the ultrasound is administered in combination with an osmotic force field.
- 19. The apparatus of claim 9 wherein the ultrasound is administered in combination with chemical enhancers and mechanical forces.
- 20. The apparatus of claim 1 wherein the molecules to be transported are drugs the patient is in need of.
- 21. The apparatus of claim 9 wherein the compound to be transported is an analyte to be measured.
- 22. The apparatus of claim 9 wherein the ultrasound is pulsed.
- 23. The method of use of the apparatus of any of claims 9-21 in enhancing transport of molecules through the skin.
- 22. A composition for enhancing delivery of drugs across the skin comprising drug encapsulated in a liposome or polymeric carrier for application to the skin and applying ultrasound for a period of time effective to deliver.

- 23. The composition of claim 22 wherein the microparticle is coated with a lipophilic or hydrophilic material enhancing transdermal penetration.
- 24. The composition of claim 22 wherein the material is a hydrophilic molecule couple to a synthetic biodegradable polymer forming the microparticle.

AMENDED SHEET (ARTICLE 19)

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)